eFFECTOR Therapeutics, Inc. LWK1.SG Stock
eFFECTOR Therapeutics, Inc. Price Chart
eFFECTOR Therapeutics, Inc. LWK1.SG Financial and Trading Overview
| eFFECTOR Therapeutics, Inc. stock price | 9.25 EUR |
| Previous Close | 0.96 EUR |
| Open | 0.86 EUR |
| Bid | 0.87 EUR x N/A |
| Ask | 0.89 EUR x N/A |
| Day's Range | 0.86 - 0.86 EUR |
| 52 Week Range | 0.31 - 1.51 EUR |
| Volume | 0 EUR |
| Avg. Volume | 190 EUR |
| Market Cap | 52.34M EUR |
| Beta (5Y Monthly) | 0.359823 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -17.08 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
LWK1.SG Valuation Measures
| Enterprise Value | 35.75M EUR |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 14.7311735 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 10.061 |
| Enterprise Value/EBITDA | -1.012 |
Trading Information
eFFECTOR Therapeutics, Inc. Stock Price History
| Beta (5Y Monthly) | 0.359823 |
| 52-Week Change | -25.53% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 1.51 EUR |
| 52 Week Low | 0.31 EUR |
| 50-Day Moving Average | 0.55 EUR |
| 200-Day Moving Average | 0.51 EUR |
LWK1.SG Share Statistics
| Avg. Volume (3 month) | 190 EUR |
| Avg. Daily Volume (10-Days) | 100 EUR |
| Shares Outstanding | 59.95M |
| Float | 27.48M |
| Short Ratio | N/A |
| % Held by Insiders | 7.90% |
| % Held by Institutions | 64.03% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -996.087% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -61.93% |
| Return on Equity (ttm) | -350.10% |
Income Statement
| Revenue (ttm) | 3.55M EUR |
| Revenue Per Share (ttm) | 0.09 EUR |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | -19760000 EUR |
| EBITDA | -35315000 EUR |
| Net Income Avi to Common (ttm) | -35748000 EUR |
| Diluted EPS (ttm) | -0.74 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 19.01M EUR |
| Total Cash Per Share (mrq) | 0.45 EUR |
| Total Debt (mrq) | 20.35M EUR |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 0.784 |
| Book Value Per Share (mrq) | -0.114 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -27039000 EUR |
| Levered Free Cash Flow (ttm) | -13856125 EUR |
Profile of eFFECTOR Therapeutics, Inc.
| Country | Germany |
| State | CA |
| City | Solana Beach |
| Address | 142 North Cedros Avenue |
| ZIP | 92075 |
| Phone | 858 925 8215 |
| Website | https://effector.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 15 |
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors and in combination with fulvestrant and abemaciclib in a Phase 2a open-label expansion cohort to treat patients with ER+ breast cancer. eFFECTOR Therapeutics, Inc. has a research collaboration and license agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.
Q&A For eFFECTOR Therapeutics, Inc. Stock
What is a current LWK1.SG stock price?
eFFECTOR Therapeutics, Inc. LWK1.SG stock price today per share is 9.25 EUR.
How to purchase eFFECTOR Therapeutics, Inc. stock?
You can buy LWK1.SG shares on the Stuttgart exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for eFFECTOR Therapeutics, Inc.?
The stock symbol or ticker of eFFECTOR Therapeutics, Inc. is LWK1.SG.
Which industry does the eFFECTOR Therapeutics, Inc. company belong to?
The eFFECTOR Therapeutics, Inc. industry is Biotechnology.
How many shares does eFFECTOR Therapeutics, Inc. have in circulation?
The max supply of eFFECTOR Therapeutics, Inc. shares is 3M.
What is eFFECTOR Therapeutics, Inc. Price to Earnings Ratio (PE Ratio)?
eFFECTOR Therapeutics, Inc. PE Ratio is now.
What was eFFECTOR Therapeutics, Inc. earnings per share over the trailing 12 months (TTM)?
eFFECTOR Therapeutics, Inc. EPS is -17.08 EUR over the trailing 12 months.
Which sector does the eFFECTOR Therapeutics, Inc. company belong to?
The eFFECTOR Therapeutics, Inc. sector is Healthcare.